Bioniq, a developer of personalised supplements based on blood biomarker analysis, has entered into an agreement for the sale of its assets to Herbalife. The deal is valued at up to US$150 million.
The transaction, announced this month, is reportedly valued at a purchase price of US$55 million to be paid over five years, with an initial payment of US$10 million. The deal also includes up to US$95 million in contingent payments based on future performance. Additionally, Herbalife has obtained a call option to acquire Bioniq LAB, a separate platform focused on small molecules and peptides.
Founded in 2019 and headquartered in London, Bioniq uses a patented personalisation engine and a proprietary database of biomarkers to create bespoke supplement formulas. Its platform is used by a broad range of consumers, including elite athletes such as Cristiano Ronaldo and Diogo Dalot, both of whom are investors in the company.
The acquisition will allow Bioniq to scale its technology through the infrastructure of Herbalife, which operates in 95 markets with over two million distributors. Vadim Fedotov, Co-Founder and President of Bioniq, is expected to join the leadership team at Herbalife following the closing of the transaction.
Vadim Fedotov said “With a professional athletic career behind me, I created Bioniq to make health measurable, actionable, and accessible. Our science-driven approach, proven efficacy, and sustainable business model have positioned us as a leader in personalised nutrition. Joining Herbalife allows us to accelerate our mission and bring personalised health solutions to a global audience at scale.”
Stephan Gratziani, Chief Executive Officer of Herbalife, said “The future of health and wellness is increasingly personalised and data-driven. By combining Bioniq’s technology with our global infrastructure and Pro2col platform, we are uniquely positioned to deliver personalised nutrition to millions of consumers worldwide.”
Bioniq’s personalised supplements are expected to be offered through independent Herbalife distributors in select European countries and the United States later this year, with further international markets to follow.
Investor and professional footballer Cristiano Ronaldo added “Throughout my career, biometrics and personalised nutrition have been central to helping me perform and compete at the highest level. I’m delighted to see Bioniq’s personalised supplements become part of Herbalife’s expanding access to nutritional supplements, helping people take a more informed approach to their health, wellness and performance.”
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory approvals. Herbalife is an international health and wellness company that has been operating since 1980, providing nutrition products through a direct-selling model.
www.bioniq.com
www.herbalife.com
